Literature DB >> 18651559

Signaling pathways in medulloblastoma.

Fadila Guessous1, Yunqing Li, Roger Abounader.   

Abstract

Medulloblastoma is the most common brain tumor of childhood. Multiple signaling pathways have been associated with medulloblastoma formation and growth. These include the developmental pathways Hedgehog, (Hh) Notch, and Wnt as well as the receptor tyrosine kinases (RTK) c-Met, erbB2, IGF-R and TrkC, and the oncoprotein Myc. Here we review the involvement of these pathways in medulloblastoma malignancy with a focus on their mode of deregulation, prognostic value, functional effects, cellular and molecular mechanisms of action, and implications for therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18651559     DOI: 10.1002/jcp.21542

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  37 in total

1.  Norcantharidin impairs medulloblastoma growth by inhibition of Wnt/β-catenin signaling.

Authors:  Flora Cimmino; Maria Nunzia Scoppettuolo; Marianeve Carotenuto; Pasqualino De Antonellis; Valeria Di Dato; Gennaro De Vita; Massimo Zollo
Journal:  J Neurooncol       Date:  2011-07-07       Impact factor: 4.130

Review 2.  A contemporary review of molecular candidates for the development and treatment of childhood medulloblastoma.

Authors:  N Ceren Sümer-Turanlıgil; Emel Öykü Cetin; Yiğit Uyanıkgil
Journal:  Childs Nerv Syst       Date:  2013-01-06       Impact factor: 1.475

3.  Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma.

Authors:  Elisa Ramirez; Rajesh R Singh; Kranthi Kunkalla; Yadong Liu; Changju Qu; Christine Cain; Asha S Multani; Patrick A Lennon; Jared Jackacky; Michael Ho; Sity Dawud; Jun Gu; Su Yang; Peter C Hu; Francisco Vega
Journal:  Leuk Res       Date:  2012-07-17       Impact factor: 3.156

4.  Heparanase Modulates Shh and Wnt3a Signaling in Human Medulloblastoma Cells.

Authors:  Lon D Ridgway; Michael D Wetzel; Dario Marchetti
Journal:  Exp Ther Med       Date:  2011-03-01       Impact factor: 2.447

Review 5.  Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms.

Authors:  Chi Young Ok; Rajesh Ramachandra Singh; Francisco Vega
Journal:  Am J Pathol       Date:  2011-11-01       Impact factor: 4.307

6.  New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.

Authors:  Alessandra Rossi; Silvia Schenone; Adriano Angelucci; Martina Cozzi; Valentina Caracciolo; Francesca Pentimalli; Andrew Puca; Biagio Pucci; Raffaele La Montagna; Mauro Bologna; Maurizio Botta; Antonio Giordano
Journal:  FASEB J       Date:  2010-03-30       Impact factor: 5.191

7.  SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells.

Authors:  Chandramu Chetty; Ranadheer Dontula; Purnachandra Nagaraju Ganji; Meena Gujrati; Sajani S Lakka
Journal:  Biochem Biophys Res Commun       Date:  2011-12-20       Impact factor: 3.575

8.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

9.  REST is a novel prognostic factor and therapeutic target for medulloblastoma.

Authors:  Pete Taylor; Jason Fangusaro; Veena Rajaram; Stewart Goldman; Irene B Helenowski; Tobey MacDonald; Martin Hasselblatt; Lars Riedemann; Alvaro Laureano; Laurence Cooper; Vidya Gopalakrishnan
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

10.  Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.

Authors:  Fan Yang; Veronica Jove; Hong Xin; Michael Hedvat; Timothy E Van Meter; Hua Yu
Journal:  Mol Cancer Res       Date:  2010-01-06       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.